Joshua Pritchett, MD (@jpritchettmd) 's Twitter Profile
Joshua Pritchett, MD

@jpritchettmd

Mayo Clinic Hematologist/Oncologist. Rural Health. Digital Health. Community Engagement. Alum @MayoHemeOnc, @MayoKernScholar, @MayoMN_IMRES, @umnmedschool

ID: 1390707962986090499

calendar_today07-05-2021 16:40:06

157 Tweet

292 Takipçi

255 Takip Edilen

JCO Oncology Practice (@jcoop_asco) 's Twitter Profile Photo

#Telehealth can be deployed as a fully integrated aspect of care w/in a multisite, multiregional cancer practice w/o evidence of duplicative care and high satisfaction. Telemedicine use was highest in nonrural & younger (≤65) pts. Joshua Pritchett, MD ➡️ fal.cn/3zB1G

#Telehealth can be deployed as a fully integrated aspect of care w/in a multisite, multiregional cancer practice w/o evidence of duplicative care and high satisfaction. Telemedicine use was highest in nonrural &amp; younger (≤65) pts. <a href="/JpritchettMD/">Joshua Pritchett, MD</a> ➡️ fal.cn/3zB1G
Joshua Pritchett, MD (@jpritchettmd) 's Twitter Profile Photo

Thanks to collaborators Aakash Desai, MD, MPH, FASCO H. Jack West, MD, FASCO Kostas Leventakos for engaging in this piece which highlights an important conversation re: access to SOC for trial participants (also Dr. Caleb Smith, not on X). Really proud to have been part of this work. Available now via Open Access.

Joshua Pritchett, MD (@jpritchettmd) 's Twitter Profile Photo

If anyone is interested this is a great opportunity to work with one of the best and brightest young investigators I know Aakash Desai, MD, MPH, FASCO. #DesaiLab. Congrats brother, keep pushing!

Thomas H. Lee, MD (@thomashleemd) 's Twitter Profile Photo

Terrific care redesign for important population from Mayo Clinic. Remote Patient Monitoring to Transform Management of Febrile Neutropenia in Cancer Patients | NEJM Catalyst catalyst.nejm.org/doi/full/10.10…

Joshua Pritchett, MD (@jpritchettmd) 's Twitter Profile Photo

Yes, it was on April 1st… But I can confirm this is no joke! Grateful for the re-post and support from NEJM. #RPM has helped catalyze a new paradigm of care for #cancer patients Mayo Clinic. And feedback from patients has been overwhelmingly positive. Onward!

Johnathan Ebben MD, PhD (@johnebbenmdphd) 's Twitter Profile Photo

#TumorBoardTuesday Shruti Patel, MD Narjust Florez, MD, FASCO Patrick Forde Nathan A. Pennell MD, PhD, FASCO Benjamin Levy Non Small Cell Lung GrepMed Mike Pishvaian Ticiana Batista (Leal) @esinghimd nan.sethakorn 7/8 #TumorBoardTuesday 🎀 Although periop IO is a new SOC in #NSCLC, it isn't accessible yet to everyone. Only an estimated 15% of people with #lungcancer around the world have access. Narjust Florez, MD, FASCO reminds that we need to extend the benefits of the science to all people.

Kathryn Ruddy (@kathrynruddymd) 's Twitter Profile Photo

E2C2 (an NCI Moonshot IMPACT trial), led by Dr. Andrea Cheville, found that collaborative care reduces symptoms, especially anxiety and depression, in patients with cancer ⁦Mayo Clinic Comprehensive Cancer Center⁩ ⁦National Cancer Institute⁩ ⁦ASCO

E2C2 (an NCI Moonshot IMPACT trial), led by Dr. Andrea Cheville, found that collaborative care reduces symptoms, especially anxiety and depression, in patients with cancer ⁦<a href="/MayoCancerCare/">Mayo Clinic Comprehensive Cancer Center</a>⁩ ⁦<a href="/theNCI/">National Cancer Institute</a>⁩ ⁦<a href="/ASCO/">ASCO</a>⁩
Joshua Pritchett, MD (@jpritchettmd) 's Twitter Profile Photo

Proud to publish this review in collaboration with a wonderful colleague Ugur Sener Mayo Clinic Neuro Mayo Clinic Comprehensive Cancer Center. Since #COVID19, #Telehealth has remained an invaluable resource for #neurooncology patients cared for across Mayo Clinic. link.springer.com/article/10.100…

Ben Derman (@bdermanmd) 's Twitter Profile Photo

What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in Blood Cancer Journal nature.com/articles/s4140…

What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in <a href="/BloodCancerJnl/">Blood Cancer Journal</a> nature.com/articles/s4140…
Jasmine Kamboj, MD, FASCO (@jasminekambojmd) 's Twitter Profile Photo

Thanks Joshua Pritchett, MD for representing us at the #ASCOQLTY25. Amazing #leadership display through your efforts to put together work around #telemedicine and #priorauthorization. Thanks Wade Swenson Ruiling Yuan Emily McGovern (Westergard), DO Dr Zack Schroeder and Dr Jon Ticku for